Search

Your search keyword '"Steichen, Olivier"' showing total 424 results
Start Over Author "Steichen, Olivier"
424 results on '"Steichen, Olivier"'

4. Prevalence and bleeding risk associated with the concomitant use of direct oral anticoagulants and antiarrhythmic drugs in patients with atrial fibrillation, based on the French healthcare insurance database

Author

Gosselin, Laëtitia, Vilcu, Ana-Maria, Souty, Cécile, Steichen, Olivier, Launay, Titouan, Conte, Cécile, Saint-Salvi, Béatrice, Turbelin, Clément, Sarazin, Marianne, Blanchon, Thierry, Hanslik, Thomas, Lapeyre-Mestre, Maryse, and Rossignol, Louise

Published
2023
Full Text
View/download PDF

10. International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers

Author

Amar, Laurence, Pacak, Karel, Steichen, Olivier, Akker, Scott A., Aylwin, Simon J. B., Baudin, Eric, Buffet, Alexandre, Burnichon, Nelly, Clifton-Bligh, Roderick J., Dahia, Patricia L. M., Fassnacht, Martin, Grossman, Ashley B., Herman, Philippe, Hicks, Rodney J., Januszewicz, Andrzej, Jimenez, Camilo, Kunst, Henricus P. M., Lewis, Dylan, Mannelli, Massimo, Naruse, Mitsuhide, Robledo, Mercedes, Taïeb, David, Taylor, David R., Timmers, Henri J. L. M., Treglia, Giorgio, Tufton, Nicola, Young, William F., Lenders, Jacques W. M., Gimenez-Roqueplo, Anne-Paule, and Lussey-Lepoutre, Charlotte

Published
2021
Full Text
View/download PDF

17. Urine concentration impairment in sickle cell anemia: genuine nephrogenic diabetes insipidus or osmotic diuresis?

Author

de Berny, Quentin, Saint-Jacques, Camille, Santin, Aline, Mattioni, Sarah, Steichen, Olivier, Chieze, Rémi, Frochot, Vincent, Letavernier, Emmanuel, Lionnet, François, and Haymann, Jean-Philippe

Subjects
DIABETES insipidus, SICKLE cell anemia, DIURESIS, VASOPRESSIN, URINE
Abstract

The urine concentration impairment responsible for hyposthenuria in sickle cell nephropathy is currently thought to be a consequence of renal medulla lesions, which lead to nephrogenic diabetes insipidus. The objective of the present study was to investigate the mechanism of hyposthenuria in patients with sickle cell anemia. We performed an observational study of patients with homozygous SS sickle cell anemia and data available on the fasting plasma antidiuretic hormone (ADH) concentration. A total of 55 patients were analyzed. The fasting plasma ADH values ranged from 1.2 to 15.4 pg/mL, and 82% of the patients had elevated ADH values and low fasting urine osmolality (<505 mosmol/kgH2O). Plasma ADH was positively associated with plasma tonicity and natremia (P < 0.001). None of the patients experienced polyuria and fasting free water clearance was negative in all cases, thus, ruling out nephrogenic diabetes insipidus. The tertile groups did not differ with regard to fasting urine osmolality, plasma renin level, mGFR, or several hemolysis biomarkers. The negative fasting free water clearance in all cases and the strong association between 24-h osmolal clearance and 24-h diuresis favors the diagnosis of osmotic diuresis due to an impaired medullary gradient, rather than lesions to collecting tubule. NEW & NOTEWORTHY The urine concentration impairment in sickle cell anemia is an osmotic diuresis related to an impaired renal medullary gradient leading to an ADH plateau effect. The fasting plasma ADH was high in the context of a basic state of close-to-maximal urine concentration probably driven by short nephrons maintaining a cortex-outer medullary gradient (about 400 milliosmoles). The patients had a low daily osmoles intake without evidence of thirst dysregulation so no one experienced polyuria. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. SFE/SFHTA/AFCE primary aldosteronism consensus: Introduction and handbook

Author

Amar, Laurence, Baguet, Jean Philippe, Bardet, Stéphane, Chaffanjon, Philippe, Chamontin, Bernard, Douillard, Claire, Durieux, Pierre, Girerd, Xaxier, Gosse, Philippe, Hernigou, Anne, Herpin, Daniel, Houillier, Pascal, Jeunemaitre, Xavier, Joffre, Francis, Kraimps, Jean-Louis, Lefebvre, Hervé, Ménégaux, Fabrice, Mounier-Véhier, Claire, Nussberger, Juerg, Pagny, Jean-Yves, Pechère, Antoinette, Plouin, Pierre-François, Reznik, Yves, Steichen, Olivier, Tabarin, Antoine, Zennaro, Maria-Christina, Zinzindohoue, Franck, and Chabre, Olivier

Published
2016
Full Text
View/download PDF

29. Prevalence of Long Covid in the General Adult Population According to Different Definitions and Sociodemographic and Infection Characteristics. A Nationwide Random Sampling Survey in France after the Omicron Waves in Autumn 2022

Author

Coste, Joël, primary, Delpierre, Cyrille, additional, Richard, Jean-Baptiste, additional, Alleaume, Caroline, additional, Gallay, Anne, additional, Beltzer, Nathalie, additional, Tebeka, Sarah, additional, Lemogne, Cédric, additional, Robineau, Olivier, additional, Steichen, Olivier, additional, and Makovski, Tatjana T., additional

Published
2023
Full Text
View/download PDF

30. Risk of hospitalisation for serious colchicine intoxication after concomitant exposure to pristinamycin: A nationwide healthcare database study

Author

Souty, Cécile, primary, Vilcu, Ana-Maria, additional, Conte, Cécile, additional, Saint-Salvi, Béatrice, additional, Sarazin, Marianne, additional, Rossignol, Louise, additional, Blanchon, Thierry, additional, Hanslik, Thomas, additional, Lapeyre-Mestre, Maryse, additional, and Steichen, Olivier, additional

Published
2022
Full Text
View/download PDF

31. External validation of prognostic scores for COVID-19: a multicenter cohort study of patients hospitalized in Greater Paris University Hospitals

Author

Lombardi, Yannis, Azoyan, Loris, Szychowiak, Piotr, Bellamine, Ali, Lemaitre, Guillaume, Bernaux, Mélodie, Daniel, Christel, Leblanc, Judith, Riller, Quentin, Steichen, Olivier, Ancel, Pierre-Yves, Bauchet, Alain, Beeker, Nathanael, Benoit, Vincent, Bey, Romain, Bourmaud, Aurélie, Bréant, Stéphane, Burgun, Anita, Carrat, Fabrice, Caucheteux, Charlotte, Champ, Julien, Cormont, Sylvie, Dubiel, Julien, Duclos, Catherine, Esteve, Loic, Frank, Marie, Garcelon, Nicolas, Gramfort, Alexandre, Griffon, Nicolas, Grisel, Olivier, Guilbaud, Martin, Hassen-Khodja, Claire, Hemery, François, Hilka, Martin, Jannot, Anne Sophie, Lambert, Jerome, Layese, Richard, Lebouter, Léo, Leprovost, Damien, Lerner, Ivan, Sallah, Kankoe Levi, Maire, Aurélien, Mamzer, Marie-France, Martel, Patricia, Mensch, Arthur, Moreau, Thomas, Neuraz, Antoine, Orlova, Nina, Paris, Nicolas, Rance, Bastien, Ravera, Hélène, Rozes, Antoine, Rufat, Pierre, Salamanca, Elisa, Sandrin, Arnaud, Serre, Patricia, Tannier, Xavier, Treluyer, Jean-Marc, van Gysel, Damien, Varoquaux, Gael, Vie, Jill-Jênn, Wack, Maxime, Wajsburt, Perceval, Wassermann, Demian, Zapletal, Eric, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Méthodes computationnelles et mathématiques pour comprendre la société et la santé à partir de données (SODA), Inria Saclay - Ile de France, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria), Laboratoire d'Informatique Médicale et Ingénierie des Connaissances en e-Santé (LIMICS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Sorbonne Paris Nord, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Health data- and model- driven Knowledge Acquisition (HeKA), Inria de Paris, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité)-École Pratique des Hautes Études (EPHE), Imagine - Institut des maladies génétiques (IHU) (Imagine - U1163), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Centre d'Immunologie et de Maladies Infectieuses (CIMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Direction générale déléguée à l'innovation (DGD-I), Institut National de Recherche en Informatique et en Automatique (Inria), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de Référence Maladies auto-immunes Systémiques Rares [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sorbonne Université (SU), Inria Siège, Service de Département de médecine interne et immunologie clinique [CHU Pitié-Salpêtrière] (DMIIC), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and Gestionnaire, HAL Sorbonne Université 5

Subjects
Adult, Paris, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Original, [SDV]Life Sciences [q-bio], 030204 cardiovascular system & hematology, Critical Care and Intensive Care Medicine, law.invention, Cohort Studies, Hospitals, University, 03 medical and health sciences, 0302 clinical medicine, law, Anesthesiology, medicine, Humans, 030212 general & internal medicine, Mortality, Retrospective Studies, [SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology, Receiver operating characteristic, SARS-CoV-2, business.industry, External validation, COVID-19, Prognosis, University hospital, Intensive care unit, 3. Good health, Intensive Care Units, Editorial, SARS-CoV2, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, Emergency medicine, Cohort, business, Cohort study
Abstract

Purpose The Coronavirus disease 2019 (COVID-19) has led to an unparalleled influx of patients. Prognostic scores could help optimizing healthcare delivery, but most of them have not been comprehensively validated. We aim to externally validate existing prognostic scores for COVID-19. Methods We used “COVID-19 Evidence Alerts” (McMaster University) to retrieve high-quality prognostic scores predicting death or intensive care unit (ICU) transfer from routinely collected data. We studied their accuracy in a retrospective multicenter cohort of adult patients hospitalized for COVID-19 from January 2020 to April 2021 in the Greater Paris University Hospitals. Areas under the receiver operating characteristic curves (AUC) were computed for the prediction of the original outcome, 30-day in-hospital mortality and the composite of 30-day in-hospital mortality or ICU transfer. Results We included 14,343 consecutive patients, 2583 (18%) died and 5067 (35%) died or were transferred to the ICU. We examined 274 studies and found 32 scores meeting the inclusion criteria: 19 had a significantly lower AUC in our cohort than in previously published validation studies for the original outcome; 25 performed better to predict in-hospital mortality than the composite of in-hospital mortality or ICU transfer; 7 had an AUC > 0.75 to predict in-hospital mortality; 2 had an AUC > 0.70 to predict the composite outcome. Conclusion Seven prognostic scores were fairly accurate to predict death in hospitalized COVID-19 patients. The 4C Mortality Score and the ABCS stand out because they performed as well in our cohort and their initial validation cohort, during the first epidemic wave and subsequent waves, and in younger and older patients. Supplementary Information The online version contains supplementary material available at 10.1007/s00134-021-06524-w.

Published
2021
Full Text
View/download PDF

32. Building an Ontology of Hypertension Management

Author

Steichen, Olivier, Daniel-Le Bozec, Christel, Jaulent, Marie-Christine, Charlet, Jean, Carbonell, Jaime G., editor, Siekmann, Jörg, editor, Bellazzi, Riccardo, editor, Abu-Hanna, Ameen, editor, and Hunter, Jim, editor

Published
2007
Full Text
View/download PDF

33. ‘Involve me and I learn’: an experiential teaching approach to improve dyspnea awareness in medical residents

Author

Decavèle, Maxens, Serresse, Laure, Gay, Frédérick, Nion, Nathalie, Lavault, Sophie, Freund, Yonathan, Niérat, Marie-Cécile, Steichen, Olivier, Demoule, Alexandre, Morélot-Panzini, Capucine, Similowski, Thomas, Neurophysiologie Respiratoire Expérimentale et Clinique (UMRS 1158), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Sorbonne Université (SU), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], CHU Tenon [AP-HP], Laboratoire d'Informatique Médicale et Ingénierie des Connaissances en e-Santé (LIMICS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Sorbonne Paris Nord, and Balse, Elise

Subjects
Experiential learning, medical residents, [SDV] Life Sciences [q-bio], respiratory suffering, medical trainees, [SDV]Life Sciences [q-bio], experimental dyspnea, personal experience, General Medicine, dyspnea, symptoms experience, empathy enhancing, Education
Abstract

International audience; Background: Dyspnea is a frightening and debilitating experience. It attracts less attention than pain ('dyspnea invisibility'), possibly because of its non-universal nature. We tested the impact of self-induced experimental dyspnea on medical residents.Materials and methods: During a teaching session following the principles of experiential learning, emergency medicine residents were taught about dyspnea theoretically, observed experimental dyspnea in their teacher, and personally experienced self-induced dyspnea. The corresponding psychophysiological reactions were described. Immediate and 1-year evaluations were conducted to assess course satisfaction (overall 0-20 grade) and the effect on the understanding of what dyspnea represents for patients.Results: Overall, 55 emergency medicine residents participated in the study (26 men, median age 26 years). They were moderately satisfied with previous dyspnea teaching (6 [5-7] on a 0-10 numerical rating scale [NRS]) and expressed a desire for an improvement in the teaching (8 [7-9]). Immediately after the course they reported improved understanding of patients' experience (7 [6-8]), which persisted at 1 year (8 [7-9], 28 respondents). Overall course grade was 17/20 [15-18], and there were significant correlations with experimental dyspnea ratings (intensity: r = 0.318 [0.001-0.576], p = 0.043; unpleasantness: r = 0.492 [0.208-0.699], p = 0.001). In multivariate analysis, the only factor independently associated with the overall course grade was 'experiential understanding' (the experimental dyspnea-related improvement in the understanding of dyspneic patients' experience). A separate similar experiment conducted in 50 respiratory medicine residents yielded identical results.Conclusions: This study suggests that, in advanced medical residents, the personal discovery of dyspnea can have a positive impact on the understanding of what dyspnea represents for patients. This could help fight dyspnea invisibility.

Published
2022
Full Text
View/download PDF

35. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms

Author

Amar, Laurence, Pacak, Karel, Steichen, Olivier, Akker, Scott, Aylwin, Simon, Baudin, Eric, Buffet, Alexandre, Burnichon, Nelly, Clifton-Bligh, Roderick, Dahia, Patricia, Fassnacht, Martin, Grossman, Ashley, Herman, Philippe, Hicks, Rodney, Januszewicz, Andrzej, Jimenez, Camilo, Kunst, Henricus, Lewis, Dylan, Mannelli, Massimo, Naruse, Mitsuhide, Robledo, Mercedes, Taïeb, David, Taylor, David, Timmers, Henri, Treglia, Giorgio, Tufton, Nicola, Young, William, Lenders, Jacques, Gimenez-Roqueplo, Anne-Paule, Lussey-Lepoutre, Charlotte, Ambrosini, Valentina, Kunikowska, Jolanta, Bodei, Lisa, Bouvier, Catherine, Capdevila, Jaume, Cremonesi, Marta, De Herder, Wouter, Dromain, Clarisse, Falconi, Massimo, Fani, Melpomeni, Fanti, Stefano, Kabasakal, Levent, Kaltsas, Gregory, Lewington, Val, Minozzi, Silvia, Cinquini, Michela, Öberg, Kjell, Oyen, Wim. J.G., O'Toole, Dermot, Pavel, Marianne, Ruszniewski, Philippe, Scarpa, Aldo, Strosberg, Jonathan, Sundin, Anders, Virgolini, Irene, WILD, Damian, Herrmann, Ken, Yao, James, Ambrosini V., Kunikowska J., Baudin E., Bodei L., Bouvier C., Capdevila J., Cremonesi M., de Herder W.W., Dromain C., Falconi M., Fani M., Fanti S., Hicks R.J., Kabasakal L., Kaltsas G., Lewington V., Minozzi S., Cinquini M., Oberg K., Oyen W.J.G., O'Toole D., Pavel M., Ruszniewski P., Scarpa A., Strosberg J., Sundin A., Taieb D., Virgolini I., Wild D., Herrmann K., Yao J., Service de médecine nucléaire [Marseille], Université de la Méditerranée - Aix-Marseille 2-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Centre Européen de Recherche en Imagerie médicale (CERIMED), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-École Centrale de Marseille (ECM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Centre National de la Recherche Scientifique (CNRS), and Internal Medicine

Subjects
0301 basic medicine, Cancer Research, medicine.medical_specialty, Consensus, Medizin, Consensu, Disease, Rare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9], Article, Pheochromocytoma, 03 medical and health sciences, 0302 clinical medicine, SDG 3 - Good Health and Well-being, Paraganglioma, medicine, Animals, Humans, medicine.diagnostic_test, business.industry, Magnetic resonance imaging, medicine.disease, 3. Good health, Molecular Imaging, Clinical trial, Neuroendocrine neoplasm, Neuroendocrine Tumors, 030104 developmental biology, medicine.anatomical_structure, Oncology, Positron emission tomography, Neuroendocrine neoplasms, 030220 oncology & carcinogenesis, Radionuclide therapy, Molecular imaging, PRRT, Radiology, Radiopharmaceuticals, Pancreas, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

Contains fulltext : 238612.pdf (Publisher’s version ) (Closed access) Nuclear medicine plays an increasingly important role in the management neuroendocrine neoplasms (NEN). Somatostatin analogue (SSA)-based positron emission tomography/computed tomography (PET/CT) and peptide receptor radionuclide therapy (PRRT) have been used in clinical trials and approved by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). European Association of Nuclear Medicine (EANM) Focus 3 performed a multidisciplinary Delphi process to deliver a balanced perspective on molecular imaging and radionuclide therapy in well-differentiated neuroendocrine tumours (NETs). NETs form in cells that interact with the nervous system or in glands that produce hormones. These cells, called neuroendocrine cells, can be found throughout the body, but NETs are most often found in the abdomen, especially in the gastrointestinal tract. These tumours may also be found in the lungs, pancreas and adrenal glands. In addition to being rare, NETs are also complex and may be difficult to diagnose. Most NETs are non-functioning; however, a minority present with symptoms related to hypersecretion of bioactive compounds. NETs often do not cause symptoms early in the disease process. When diagnosed, substantial number of patients are already found to have metastatic disease. Several societies' guidelines address Neuroendocrine neoplasms (NENs) management; however, many issues are still debated, due to both the difficulty in acquiring strong clinical evidence in a rare and heterogeneous disease and the different availability of diagnostic and therapeutic options across countries. EANM Focus 3 reached consensus on employing (68)gallium-labelled somatostatin analogue ([(68)Ga]Ga-DOTA-SSA)-based PET/CT with diagnostic CT or magnetic resonance imaging (MRI) for unknown primary NET detection, metastatic NET, NET staging/restaging, suspected extra-adrenal pheochromocytoma/paraganglioma and suspected paraganglioma. Consensus was reached on employing (18)fluorine-fluoro-2-deoxyglucose ([(18)F]FDG) PET/CT in neuroendocrine carcinoma, G3 NET and in G1-2 NET with mismatched lesions (CT-positive/[(68)Ga]Ga-DOTA-SSA-negative). Peptide receptor radionuclide therapy (PRRT) was recommended for second line treatment for gastrointestinal NET with [(68)Ga]Ga-DOTA-SSA uptake in all lesions, in G1/G2 NET at disease progression, and in a subset of G3 NET provided all lesions are positive at [(18)F]FDG and [(68)Ga]Ga-DOTA-SSA. PRRT rechallenge may be used for in patients with stable disease for at least 1 year after therapy completion. An international consensus is not only a prelude to a more standardised management across countries but also serves as a guide for the direction to follow when designing new research studies.

Published
2021
Full Text
View/download PDF

42. Risk of bleeding associated with nonsteroidal anti‐inflammatory drug use in patients exposed to antithrombotic therapy: a case‐crossover study

Author

Paternoster, Morgane, primary, Steichen, Olivier, additional, Lapeyre‐Mestre, Maryse, additional, Blanchon, Thierry, additional, Rossignol, Louise, additional, Vilcu, Ana‐Maria, additional, Launay, Titouan, additional, Sarazin, Marianne, additional, Bagheri, Haleh, additional, Conte, Cécile, additional, Turbelin, Clément, additional, Hanslik, Thomas, additional, and Souty, Cécile, additional

Published
2021
Full Text
View/download PDF

46. IS THE CONTROL OF CARDIOVASCULAR RISK FACTORS IS DIFFERENT IN PRIMARY AND SECONDARY PREVENTION? COMPARISON OF 2 COHORTS OF HYPERTENSIVE PATIENTS WITHIN 10 YEARS

Author

Lopez-Sublet, Marilucy, primary, Lequeux, Benoit, additional, Gallo, Antoine, additional, Dourmap, Caroline, additional, Delsart, Pascal, additional, Coz, Sylvie Regnier Le, additional, Steichen, Olivier, additional, Lamirault, Guillaume, additional, Boulestreau, Romain, additional, Ott, Julien, additional, Dimitrov, Yves, additional, Sautenet, Benedicte, additional, Feit, Bertrand, additional, Artifoni, Mathieu, additional, Baguet, Severine, additional, Irigoin, Marc, additional, Mourad, Jean Jacques, additional, Le Jeune, Sylvain, additional, and Sosner, Philippe, additional

Published
2021
Full Text
View/download PDF

49. Reply

Author

Seguret, David, primary and Steichen, Olivier, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results